



UCB reinforces commitment to epilepsy community at European congress

- *People with epilepsy share experiences at UCB-sponsored session of the 12th European Conference on Epilepsy and Society*

Porto, PORTUGAL, August 26th — UCB is reinforcing its commitment to the epilepsy community at this week's 12th European Conference on Epilepsy and Society (ECES), in Porto, Portugal, by showing how the compelling stories of those living with epilepsy can inspire, motivate and encourage others to live beyond their epilepsy. The congress, which takes as its theme, *Epilepsy – So What?* is analysing many aspects of living with epilepsy and aims to reduce the stigma of the disease.

At a UCB-sponsored session, *Inspiring Voices of People Living with Epilepsy*, Julie, the mother of a child with epilepsy, Monica, who has grown up with epilepsy, and Alexander, a doctor who developed epilepsy after a lifetime researching the disease, shared their personal experiences.

"By telling their stories, people like Julie, Monica and Alexander are making an important difference to the lives of others in similar situations, and those who care for them. They don't have all the answers, but each has developed strategies and solutions that are helpful to others," comments Dr Lode Dewulf, Chief Medical Affairs Officer, UCB.

When Alexander started having seizures, he realised the differences between his medical understanding of living with epilepsy and the reality as a patient:

"My newfound perspective on the anxiety, uncertainty, and fears of those living with epilepsy has enabled me to be a more effective researcher, a more compassionate doctor, and a more knowledgeable teacher for my students. In my opinion, this aspect in the care of epilepsy patients deserves much more attention from the profession and it is my hope that by speaking here today, I can help to make this happen," he said.

UCB has developed innovative patient programs including educational and other initiatives, with the goal of delivering solutions that go beyond the benefits of medicines.

The ECES is an important event in the epilepsy congress calendar as it focuses on the social aspects of the disease and facilitates communication and exchange of ideas among people with epilepsy and professionals in the field from across Europe.

As part of its ongoing initiatives to increase awareness and understanding of epilepsy, UCB also supports the Excellence in Epilepsy Journalism Award. This is a joint initiative between UCB and the International Bureau for Epilepsy (IBE) which recognizes and rewards outstanding contributions to epilepsy journalism. Entries should have been



published or broadcast between 30th June 2009 and 29th October 2010. The closing date for receipt of entries for the Award is 29th October 2010.

Further information

*Eimear O'Brien, Associate Director, Global CNS Communications, UCB Group
T +32.2.559.9271, Eimear.O'Brien@ucb-group.com*

About Epilepsy

Epilepsy is a chronic neurological disorder affecting 50 million people worldwide. It is caused by abnormal, excessive electrical discharges of the nerve cells or neurons in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes and effective classification guides treatment and prognosis.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.